Clofarabine Patent Expiration
Clofarabine is Used for treating pediatric patients aged 1 to 21 years with relapsed or refractory acute lymphoblastic leukemia. It was first introduced by Genzyme Corp
Clofarabine Patents
Given below is the list of patents protecting Clofarabine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Clolar |
US5661136 (Pediatric) | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jul 14, 2018
(Expired) | Genzyme |
| Clolar | US5661136 | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jan 14, 2018
(Expired) | Genzyme |
Clofarabine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Clofarabine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
